The developer, James Sheridan wished Cancell to be affordable to all cancer sufferers in the world.
In negotiations with drug companies he
insisted on reasonable prices.
...The developer, James Sheridan, felt that Cancell would have completely eliminated the tumor masses if the test was conducted for a longer period.
harassed the developer James Sheridan
and prevented labs from testing his
compound.Eventually they placed an injunction against him from distributing Cancell
even though no one had reported any adverse side effects.
The FDA's position on Cancell
may look different from their point of view.Sheridan
was distributing a compound that FDA
did not approve, therefore the FDA
felt obliged to stop his
can't even get acknowledged by the medical community because he
isn't a medical doctor.
Effectiveness and Response Time
By 1940, Sheridan
had a compound which he
tested to be 38% effective.He
continued improving the formulation using laboratory animals.Eventually over 20,000 animal experiments were performed and, by 1953 the development stage ended.
failed to get a lab to perform a toxicity test on Entelev, one interested group succeeded in getting the test performed by changing the name.
...Entelev was developed by a chemist, James Sheridan of Rosell, Michigan.
original formula the following names have been used: Sheridan's Formula, Jim's Juice, Crocinic Acid, JS-114, JS-101, 126-F, Entelev, Cancell
, Cantron, and Protocel. Sheridan
theorized the possibility of chemically controlling the energy needed by the cells of our body to cause energy low cancer cells to revert to a state where the body can eliminate them as foreign matter.The theory postulates that cancer cells are too energy low to proceed with their normal development.Cancer cells stop their development just short of differentiating into a normal liver, lung, brain ... cell.Sheridan
proposed to push cancer cells backward in their development instead of try to encourage them to differentiate. Sheridan
had found a method of controlling the energy available to cells in the early 1930s after witnessing a chemical reaction called rhythmic banding in an analytical chemistry laboratory at Carnegie Tech and reading the Debye Theory, published in 1927 which explores the effects of changing the dielectric constant on reactions of positive and negative ions suggested the means to accomplish this energy reduction. About 1950, Sheridan was invited to join the staff of the Detroit Institute of Cancer Research.
performed the required chemical work on the project and the institute experts performed the animal tests.
They returned and reported that the American Cancer Society
did not approve the test because Mr. Sheridan
did not prove that he
owned the idea.Sheridan
was later fired.
Since Sherdian had worked on his idea for many years, it would be fairly easy to show that the idea was his, but Sheridan
Based on the animal testing, Sheridan
knew that Entelev was non-toxic and started giving it to friends who were at the "end of the line."Word spread of the effects it had on these people and Sheridan
started receiving requests from all over the country.Unable to refuse to give people a chance for life, he
began distributing it for free to anyone who asked for it.
had recently quit distributing Entelev in response to a court injunction because he
had not gained FDA approval.This nameless man had written six technical books, and was competent to understand the formulation so Sheridan
gave it to him, but he
didn't have the equipment for production.
Sopcak agreed to make it and eventually started working with Sheridan
and distributing it for free between 1984 and 1992.
and Sopcak decided to pay for this testing because they couldn't get help from the drug company influenced cancer agencies.
found what he
considered the best laboratory in the country in New Mexico.The cost of the toxicity test was originally $5,000.After they got the material, they called Jim
and said it would cost $7,000.Sheridan
and Sopcak still agreed.
and Sopcak agreed.
retired and no longer pursues the battle.
The Formulation Change / Name Confusion / Reputation Destruction Ed Sopcak worked with James Sheridan, the developer, by distributing Entelev (the original name for Cancell, see History above) under the name Cancell between 1984 and 1992.
Sopcak's new formula was completely clear and contained none of the chemicals that Sheridan
...by James Vincent Sheridan & James Edward Sheridan
...James V. Sheridan graduated from High School at age 17 after completing two years of Junior High in just one year.In his Senior year, he won a State Senatorial Scholarship and chose to attend Carnegie Tech in Pittsburgh ( Now Carnegie Mellon ). He spent 5 years at Carnegie Tech, Four in Undergraduate work and one as a Graduate student.During his Graduate years, he was also a member of the teaching staff.In addition, he attended one summer school at Carnegie Tech and one at the University of Pittsburgh.
By the end of his
graduate year he
had taken every advanced course in Chemistry, Physics and Math taught at Carnegie Tech
. Mr. Sheridan has spent two years working in the Analytical Lab at Dow Chemical Co. in Midland, Michigan ( 1935-1937), three years a the Detroit Institute of Cancer Research ( now the Michigan Cancer Foundation) ( 1950-1953 ), and two years at Batelle Institute in Columbus, Ohio ( 1961-1963 ). In addition, he has had a lab in his home to run mouse experiments for a substantial number of years. James V. Sheridan
is a Christian.He
believes that the basic idea of Entelev/Cancell
is a gift from God, just as athletic talent, musical ability and all other gifts are blessings from God.He
also believes in the power of prayer as described in the Bible and that the inspiration for Entelev/Cancell
came as result of prayer ( indeed his
original word for the material , ENTELEV, comes from the Greek word, "ENTELECHY" which means that part of man known only to God.
...James Vincent Sheridan is the developer and inventor of Entelev/Cancell.His
technical background is set out in the body of this article.He
provided all the technical information for the article.